Milestone Pharmaceuticals Inc. - Common Shares (MIST)
MIST moved a median of -0.32% 30 minutes after news, and 0.00% by the close. How MIST actually reacts to news — the realized, point-in-time move the market made, measured across 262 labeled events over the last three years with zero look-ahead.
MIST’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 255 |
| 30-min | -0.32% | 42% | 262 |
| 60-min | 0.00% | 46% | 262 |
| to close | 0.00% | 48% | 256 |
| Middle 50% of MIST reactions | -1.71% to +1.32% |
|---|---|
| Median reaction (30-min) | -0.32% |
| Measured reactions | 262 |
Half of all Milestone Pharmaceuticals Inc. - Common Shares news events land between -1.71% and +1.32% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MIST reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -1.93% | 30% | -2.73% |
| Coverage initiations | 13 | +1.37% | 69% | -1.37% |
| Rating reiterations | 37 | 0.00% | 49% | -1.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how MIST ranks against every other measured name →
That’s how MIST usually reacts — get an email when it moves on news →Email me when MIST moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MIST's baseline. Nothing else.
Recent MIST events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences | Press release | GlobeNewswire | +1.15% | -2.63% | |
| Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial | Press release | GlobeNewswire | -0.54% | +6.25% | |
| Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR | Press release | GlobeNewswire | -1.84% | -8.35% | |
| Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults | Press release | PR Newswire | +4.58% | +0.83% | |
| Form 8-K Milestone Pharmaceutical For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | -0.83% | |
| Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States | Press release | GlobeNewswire | -0.80% | -3.59% | |
| Milestone Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.74% | +2.61% | |
| Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes | Press release | GlobeNewswire | +2.97% | +0.85% | |
| Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) | Press release | GlobeNewswire | -2.34% | -1.40% | |
| Form 10-Q Milestone Pharmaceutical For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.11% | +1.35% | |
| Form 8-K Milestone Pharmaceutical For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | +1.35% | |
| Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.11% | +1.35% | |
| Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 | Press release | GlobeNewswire | -0.04% | -4.58% | |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.37% | -1.49% | |
| Form 8-K Milestone Pharmaceutical For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.53% | |
| Form EFFECT Milestone Pharmaceutical | SEC filing · Form EFFECT | SEC EDGAR | +0.71% | -1.41% | |
| Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Press release | GlobeNewswire | -3.60% | -2.40% | |
| Form 10-Q Milestone Pharmaceutical For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +12.50% | +7.50% | |
| Form 8-K Milestone Pharmaceutical For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +12.50% | +7.50% | |
| Form S-3 Milestone Pharmaceutical | SEC filing · Form S-3 | SEC EDGAR | -3.60% | -2.40% | |
| Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +12.50% | +7.50% | |
| Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026 | Press release | GlobeNewswire | +0.00% | +3.14% | |
| Form ARS Milestone Pharmaceutical For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.38% | +3.31% | |
| Form DEF 14A Milestone Pharmaceutical For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -1.38% | +3.31% | |
| Form DEFA14A Milestone Pharmaceutical | SEC filing · Form DEFA14A | SEC EDGAR | -1.38% | +3.31% | |
| Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT | Press release | GlobeNewswire | -2.19% | -1.46% | |
| Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.06% | -1.47% | |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.79% | +9.52% | |
| Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies | Press release | GlobeNewswire | +2.36% | +12.26% | |
| Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China | Press release | PR Newswire | +0.72% | -7.35% | |
| Form 10-K Milestone Pharmaceutical For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.24% | -15.00% | |
| Form 8-K Milestone Pharmaceutical For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | -15.00% | |
| Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session | Press release | GlobeNewswire | +0.59% | -0.59% | |
| Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 | Press release | GlobeNewswire | -1.18% | +2.94% | |
| Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -0.58% | +0.00% | |
| Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer | Press release | GlobeNewswire | -0.81% | +0.00% | |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.76% | +0.00% | |
| Form 8-K Milestone Pharmaceutical For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | -3.00% | |
| Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | Press release | GlobeNewswire | +1.50% | -3.00% | |
| Form 8-K Milestone Pharmaceutical For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.52% | -2.52% | |
| Form 8-K Milestone Pharmaceutical For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +0.49% | |
| Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency | Press release | GlobeNewswire | +0.49% | +0.49% | |
| Form 8-K Milestone Pharmaceutical For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -14.74% | -19.42% | |
| Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | Press release | GlobeNewswire | -14.74% | -19.42% | |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.97% | -2.60% | |
| Form 10-Q Milestone Pharmaceutical For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.53% | -1.03% | |
| Form 8-K Milestone Pharmaceutical For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | -1.03% | |
| Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | Press release | GlobeNewswire | -0.53% | -1.03% | |
| Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.90% | -2.17% | |
| Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 | Press release | GlobeNewswire | -0.51% | -5.13% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MIST section they belong to.
Where else MIST is measured.
MIST earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Milestone Pharmaceuticals Inc. - Common Shares's median reaction calculated?
Every labeled MIST news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 262 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of MIST's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MIST's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.